Chronic pain affects many dogs and cats, and is a common symptom of conditions such as osteoarthritis and cancer. Both of these conditions are more likely to occur as a pet ages, and as the pet population is aging in general, the need for long-term pain management options is expected to increase. Nexvet has delivered a significant amount of clinical data supporting the blocking of nerve growth factor (NGF) in dogs, cats and horses as a way of controlling osteoarthritic pain, a pathway that has also been validated in humans in multiple phase II and III human clinical trials. Nexvet has two anti-NGF mAbs in late-stage development as monthly subcutaneous injectables: ranevetmab for dogs, and NV-02 for cats.

What is an anti-NGF mAb?

Monoclonal antibodies (mAbs) are a type of biologic therapy. “anti-NGF” means the mAb targets and inhibits nerve growth factor (NGF), a mediator of pain signaling and nerve growth in the body.


Immuno-oncology is an approach to fighting cancer that revolves around activating the immune system to attack tumors. Up to a quarter of dogs die of cancer, and its incidence is higher in older dogs. This approach has shown long-lasting efficacy in multiple human tumor types, making it an exciting line of investigation for Nexvet in canine cancer. In human medicine, blocking the interactions of PD-1 and PD-L1 has resulted in approved therapies, such as Opdivo® (nivolumab) and Keytruda® (pembrolizumab), with attractive safety profiles that demonstrate efficacy against multiple tumor types. These advancements have led to immuno-oncology (also called cancer immunotherapy) being hailed as a breakthrough for oncology, and a major investment target. The first human PD-1 inhibitor received regulatory approval in late 2014, and PD-1 inhibitors alone are predicted to achieve human sales of approximately $14 billion by 2020.


What is tumor necrosis factor?

Tumor necrosis factor (TNF) is a protein involved with inflammation, which binds to its receptor protein (the TNF receptor) on the surface of cells, such as cells involved with immunity and inflammation. By binding to TNF, an 'anti-TNF' monoclonal antibody, or mAb can prevent TNF from binding to its real receptor. This results in a reduction of the effects of TNF in the body. Successful human therapies such as Enbrel®, Remicade® and Humira® use this approach to reducing inflammation.



Chronic inflammation is seen in a variety of diseases in both dogs and cats, including irritable bowel disease, chronic kidney disease, and a wide variety of skin conditions. These can significantly impact quality-of-life and have symptoms distressing for both pet and theirs owner. Nexvet is investigating blocking tumor necrosis factor (TNF) in dogs and cats as a way of suppressing inflammation, a pathway that is the basis for several of the best-selling drugs in human healthcare including Remicade and Humira. The anti-TNF class of drugs are among the best-selling human pharmaceuticals, accounting for over $31 billion in sales in 2015. 

Allergy is a complex immune phenomenon responsible for a wide range of reactions to various stimuli. A significant proportion of atopic dermatitis cases (which are responsible for approximately 10% of vet visits) are related to allergies. Nexvet is investigating new mAbs to undisclosed biologic targets for dogs and cats that have been validated in human allergic disease.

The Nexvet research team is currently studying further mAbs that bind to canine and feline targets relevant to pain, inflammation, cancer and other chronic conditions.


Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522 

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

Get in Touch